Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
Ryan Allway June 2nd, 2021 This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 The Company approaches a significant milestone advancing from a pre-revenue biotech to in... Read more
Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
Ryan Allway May 5th, 2021 This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP)(OTCQB:TBPMF)(FSE:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )